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Objectives. Our aim was to study a population of patients with 
hypertrophic cardiomyopathy from the well defined geographic 
region of Tuscany in central Italy, a group virtually free of 
selective referral I~ias and therefore probably closely representa- 
tive of the true patient population with this disease. 
Background. Most available information on clinical course, 
natural history and prognosis of hypertrophic cardiomyopathy is 
based on data generated from tertiary referral centers and 
therefore constitutes a potentially biased perspective of the dis- 
ease process in this complex and diverse condition. 
Methods. The study group comprised 202 patients aged 1 to 74 
years (mean -+ SD 41 -+ 17) at initial diagnosis and followed up 
for 1 to 30 years (mean 10 -+ 5). 
Results. Largely with the use of single or multiple drug therapy, 
the vast majority of patients (n = 154 [76%]) were asymptomatic 
or mildly symptomatic and in stable or improved condition over 
the period of follow-up, whereas the remaining patients (n = 48 
[24%]) experienced deterioration, had substantial functional im- 
pairment or died. Of the 13 patients (6%) who died of cardiovas- 
cular causes related to hypertrophic cardiomyopathy, 11 had 
progressive congestive h art failure (including 6in the end.stage 
phase) and only 2 died suddenly. The annual mortality rate for 
cardiovascular disease was 0.6% and that due to sudden cardiac 
death was only 0.1%; the cumulative survival rate was 97%, 95% 
and 92%, respectively, at 5, 10 and 15 years of follow-up. Atrial 
fibrillation proved to be a relatively common (n = 57 [28%]) and 
particularly unfavorable clinical feature, with premature death 
occurring in 9 of the 57 patients. The cumulative survival rate 
after 15 years was 76% for patients with atrial fibrillation versus 
97% for patients with sinus rhythm. Syncope occurred in 33 
patients (16%) but did not appear to be of prognostic significance. 
Conclusions. In an unselected regional population, hypertro- 
phic cardiomyopathy had a relatively benign prognosis inconsis- 
tent with its prior characterization as a generally progressive 
disorder, based primarily on the experience of selected referral 
institutions. Sudden unexpected cardiac death was distinctly 
uncommon, although a sizable proportion of patients (particu- 
larly the subset prone to atrial fibrillation), did experience linical 
deterioration. 
(J Am CoU Cardiol 1995;26:1529-36) 
Hypertrophic ardiomyopathy is a primary cardiac disease, 
often genetically transmitted, with a diverse clinical and mor- 
phologic expression and characterized by unexplained left 
ventricular hypertrophy (1-17). Most previous tudies of this 
disease, based on populations from large tertiary referral 
centers of highly selected patients, have reported a severe 
prognosis due largely to unexpected sudden cardiac death 
(18-32). 
However, some studies (33-35) have suggested that a more 
benign clinical profile and prognosis may be characteristic of 
the overall hypertrophic cardiomyopathy disease spectrum. 
This is a potentially critical perception because it may have an 
important effect on our concepts of the disease process in 
hypertrophic cardiomyopathy and specifically oh those issues 
related to treatment s rategy and risk stratification for prema- 
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ture cardiac death (36). Consequently, in the present study we 
took advantage of a unique opportunity odescribe the clinical 
features and long-term outcome of hypertrophic cardiomyop- 
athy in a large group of unselected, consecutively identified 
patients assessed longitudinally in a well defined regional 
population from the Tuscany region in central Italy over the 
last 30 years. 
Patient selection. Ospedale di Careggi is a large community- 
based multispecialty hospital in Florence, Italy with >3,000 
inpatient beds and large outpatient departments. For -60 
years this institution has served the Florence metropolitan rea 
(population 1 million), as well as the surrounding geographic 
region of Tuscany (total population -3.5 million within 25,000 
square miles). At the time of diagnosis and during the fol- 
low-up period, study patients were living either in Florence, 
other parts of Tuscany or in immediately adjacent regions of 
Umbria (with the exception of five who were from other parts 
of Italy). Diagnosis and treatment was generally consistent 
throughout the period of follow-up, with one cardiologist 
(F.C.) assuming primary responsibility for the management of 
each patient. Although cardiac surgery is available in this 
region of Italy, specialized operative care for patients with 
©1995 by the American College of Cardiology 0735-1097/95/$9.50 
0735-1097(95)00353-6 
1530 CECCHI ET AL. JACC Vol. 26, No. 6 
HYPERTROPHIC CARDIOMYOPATHY IN TUSCANY November 15, 1995:1529-36 
obstructive hypertrophic ardiomyopathy (septal myotomy- 
myectomy) (37,38) has not been readily accessible. The diag- 
nosis of hypertrophic cardiomyopathy was based on echocar- 
diographic identification of a hypertrophied, nondilated left 
ventricle (wall thickness ---15 mm) in the absence of another 
cardiac or systemic disease capable of producing the magni- 
tude of left ventricular hypertrophy present in that patient 
(1,4,16). In patients evaluated before echocardiography was 
introduced into our clinical practice in 1977, the diagnosis of 
hypertrophic cardiomyopathy was made by virtue of the typical 
clinical, electrocardiographic (ECG), phonocardiographic, he-
modynamic and angiographic findings (2,18,20,21) and was 
subsequently confirmed by echocardiography (4). 
Between 1963 and 1992, 221 consecutive patients diagnosed 
as having hypertrophic cardiomyopathy at our institution were 
evaluated clinically on two or more occasions and followed up 
for ->1 year. Nineteen were excluded because at the time of 
initial evaluation they showed 1) associated valvular or con- 
genital heart disease (n = 5); 2) symptomatic and hemody- 
namically significant coronary artery disease documented by 
arteriography (n = 5); or 3) systemic hypertension defined as 
blood pressure ->170/100 mm Hg (n = 9). Therefore, the final 
study group consisted of 202 patients with hypertrophic car- 
diomyopathy. Of the 202 patients, 155 were from separate and 
distinct pedigrees and completely unrelated. The remaining 47 
patients were from 18 other families, each of which contributed 
two to four patients to the cohort. 
Initial clinical evaluation was defined as the time when the 
diagnosis of hypertrophic cardiomyopathy was first confirmed. 
The most recent clinical assessment was obtained uring 1992. 
Ages at initial evaluation were 1 to 74 years (mean +_ SD 41 +_ 
17); 22 (11%) were <20 years and 30 (15%) were >60 years. 
Ages at most recent evaluation were 13 to 82 years (mean 52 _+ 
16). Follow-up period from initial diagnosis was 1 to 30 years 
(mean 10.1 _+ 5); 139 patients (68%) were men. 
The vast majority of our patients (n = 176 [87%]) were 
initially identified as having hypertrophic cardiomyopathy at 
our institution, usually in the outpatient clinic. The diagnosis of 
hypertrophic cardiomyopathy was made most commonly be- 
cause of the onset of cardiac symptoms or the occurrence of 
acute events uch as atrial fibrillation, syncope, or peripheral 
embolism, or identification of an abnormal ECG. No patient 
was included solely on the basis of a diagnosis made during a 
systematic pedigree analysis (39). Patients were followed up in 
a standard fashion at -1-year intervals with clinical examina- 
tion, two-dimensional echocardiogram, 12-lead ECG, 24- to 
48-h ambulatory (Holter) ECG and treadmill exercise test. 
Cardiac catheterization a d angiography were performed in 57 
patients. 
Eehocardiography. Echocardiographic studies were per- 
formed with the use of commercially available instruments. 
Extent and distribution of left ventricular hypertrophy was 
assessed from the two-dimensional echocardiogram asprevi- 
ously described (4). Magnitude of basal subaortic gradient was 
estimated with continuous wave Doppler study (40) or by the 
magnitude and duration of mitral valve systolic anterior too- 
tion in patients tudied before the introduction of Doppler 
echocardiography at our institution (1). 
Definitions. Congestive heart failure. Heart failure was de- 
fined in the context of two distinctive profiles: 1) substantial 
functional limitation with evidence of marked pulmonary 
congestion, often associated with pulmonary edema, but with 
intact left ventricular systolic function; and 2) end-stage phase 
(41-43), characterized by progressive heart failure and left 
ventricular wall thinning (---5 mm), relative cavity enlargement 
or decreased ejection fraction. These patterns of severe heart 
failure in hypertrophic cardiomyopathy are distinct from the 
more common functional limitation associated with exertional 
dyspnea in the presence of intact systolic function. 
Sudden death. Sudden cardiac death was defined as an 
unexpected nontraumatic event occurring <! h from the onset 
of symptoms. Unexpected cardiovascular collapse occurring 
unexpectedly in the context of severe congestive heart failure 
or peripheral embolization was not regarded as sudden death. 
Medical treatment strategies. Medical therapy was di- 
rected toward control of symptoms, arrhythmias, outflow ob- 
struction and prevention of peripheral embolization. Patients 
with angina pectoris or symptoms of congestive heart failure, 
or both, were treated with beta-adrenergic blocking agents 
(usually nadolol, 80 to 160 mg/day) if obstruction was present 
or with calcium channel blockers (usually verapamil, 240 to 
360 mg/day, or nifedipine, 30 to 60 mg/day) if obstruction was 
absent. With severe congestive symptoms, diuretic agents (e.g., 
furosemide, thiazides) or an angiotensin-converting enzyme 
inhibitor (captopril) were often administered. 
Asymptomatic patients did not receive drug treatment 
except in the presence of additional clinical variables regarded 
as risk factors, such as severe outflow obstruction or ventricular 
tachycardia; amiodarone was administered in low doses 
(200 rag/day) to patients with sustained or multiple and 
repetitive runs of ventricular tachycardia on Holter ECG. In 
patients with atrial fibrillation, sinus rhythm was usually re- 
stored by direct current cardioversion, in association with 
amiodarone, and after anticoagulation was achieved with 
warfarin. 
Statistical analyses. Data were expressed as mean value _+ 
SD. Statistical analyses were performed by using a Student 
test for comparison of normally distributed ata. Univariate 
analysis for survival and event-free curves were performed by 
using Kaplan-Meier estimates (44); univariate and multivariate 
analysis for the assessment of independent risk predictors 
utilized the Cox regression model (45). 
Resu l ts  
Mortality. data. Of the 202 study patients, 13 (6%) died of 
cardiovascular causes related to hypertrophic cardiomyopathy 
during the follow-up period; 1 other died in an automobile 
accident and was excluded from the mortality statistics (Table 
1, Fig. 1). Age at death was 31 to 75 years (mean 58); 7 (53%) 
of those who died were men. Of the 13 cardiovascular deaths, 
2 were sudden and unexpected and unrelated to exertion, 
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Table 1. Demographic, Clinical and Morphologic Data in 13 Patients With Hypertrophic Cardiomyopathy-Related Death 
Echo Data at Initial Diagnosis Hemodynamic Data 
Family 
Duration History Max LV Basal PAP Mean End- 
Pt No./ At At of Follow- of HCM NYHA Class Thickness* LA LVED % LVOTG (S/D) PAW NSVI Stage Cause 
Gender Diagnosis Death Up (yr) or SD Initial Recent (mm) (mm) (mm) FS (mmHg) (mmHg) (mmHg) (Holter) AF HCM of Death 
Age (yr) 
1/M 8 32 28.0 0 II II 18t 47 - -  38 80 - -  - -  0 0 0 SD 
2/M 20 48 28.0 HCM + I IV 23 43 45 38 0:~ - -  - -  0 C + CHF 
SD 
3/F 25 40 23.2 0 II II 26t 53 40 24 100 52/12 - -  0 P 0 SD 
4/M 30 31 1.0 0 III III 24 49 41 39 60 60/34 29 0 0 0 CHFII 
5/F 34 55 21.3 0 II III 29 56 37 43 0§ 35/12 16 0 C + CHF 
6/M 40 53 12.7 HCM + II IV 30 52 41 29 32 55/25 - -  + C + CHF 
SD 
7/F 52 64 12.1 HCM + III III 20 38 40 40 0 36/15 - -  0 P 0 CHFII¶ 
SD 
8/M 53 72 18.8 0 II Ill 20 72 54 25 0:~ - -  - -  + C + CHF/R.emb, 
9/F 59 72 13.1 HCM + IV III 30 40 43 25 100 42/14 16 + C + CHF/stroke 
SD 
10/M 59 62 3.8 0 II III 26 50 44 32 0~ - -  - -  0 C + CHF/stroke 
ll/M 60 73 12.8 0 II III 28 53 48 41 0 - -  - -  + 0 0 CHF 
12/F 66 75 8.8 HCM IV IV 30 70 26 61 0 75/40 25 + C 0 CHF 
13/F 70 73 2.8 0 II III 28 47 27 22 100¢ - -  - -  0 0 0 CHFII 
*Site of maximal thickness was the ventricular septum except for Patient 2, in whom posterior free wall thickness predominated. CData based on postoperative 
echocardiogram in two patients with myotomy-myectomy; all other data are from the preoperative echocardiogram. :~Estimated with continuous wave Doppler 
echocardiography (40); all other outflow gradients were measured at cardiac catheterization, except in Patient 11, whose gradient was assessed by M-mode 
echocardiography with respect o magnitude and duration of systolic anterior motion of the mitral valve. §A 60-mm Hg gradient was provoked at cardiac catheterization; 
provocable gradients were not elicited in the other three patients without a basal gradient at catheterization. IlClinical course included one or more episodes of acute 
pulmonary edema. ¶Also, with cardiovascular complications ofbacterial endocarditis. AF = atrial fibrillation; C = chronic; CHF = congestive heart failure; D = 
diastolic; Echo = echocardiographic; F =female; FS = fractional shortening; HCM = hypertrophic cardiomyopathy; LA = left atrium; LV = left ventricular; LVED 
= left ventricular end-diastolic dimension; LVOTG = left ventricular outflow tract pressure gradient; M = male; Max = maximal; NSVT = nonsustained ventricular 
tachycardia; NYHA Class = New York Heart Association functional class; P = paroxysmal; PAP (S/D) = pulmonary artery pressure; PAW = pulmonary artery wedge 
pressure; Pt = patient; R.emb. = renal embolism; S = systolic; SD = sudden death; - -  = data not available; + = present; 0 = absent. 
occurring when the patients were 32 and 40 years of age (15 
and 8 years, respectively, after septal myotomy-myectomy); 
both patients were mildly symptomatic before death. The other 
11 deaths were related to congestive heart failure, including 3 
in patients whose final event (despite anticoagulation) was 
Figure 1. Changes in functional symptomatic state between the initial 
and most recent clinical evaluation in 202 patients with hypertrophic 
cardiomyopathy. Numbers within connecting lines indicate subsets of 
patients. C-V = cardiovascular. 
Initial Last 
Evaluation Evaluation Deaths 
.-_ 
° ,, i II ~ ~ - - - - ~ }  
~ III/IV~- @-~~-,~  
C-V 
" ~  Non-cardiac 
peripheral embolism. Six of these 11 patients had morphologic 
and functional evidence of the end-stage phase of hypertrophic 
cardiomyopathy (41-43). 
Of the 19 clinical variables examined, 4 were significantly 
associated with cardiovascular mortality by univariate analysis 
(wall thinning ---5 mm, fractional shortening <30%, New York 
Heart Association functional class III or IV at initial evalua- 
tion and atrial fibrillation); with multivariate analysis, more 
advanced functional impairment at initial evaluation was the 
only independent predictor of cardiovascular mortality (p < 
0.001). 
For the overall study group the 5-, 10- and 15-year cumu- 
lative survival rates were 97%, 95% and 92%, respectively (Fig. 
2). Over the period of follow-up the overall annual cardiovas- 
cular mortality was 0.6%. The annual mortality rate confined 
to sudden cardiac death was 0.1%. 
Clinical course. Symptoms. Symptomatic state and func- 
tional cardiovascular status at the initial and most recent 
evaluations were compared (Fig. 1). Symptoms during follow- 
up were most commonly exertional dyspnea with or without 
fatigue (n = 108) and chest pain (n -- 68, 23 with angina and 
45 with atypical pain); frequently patients experienced palpi- 
tation (n = 95) or syncope (n = 25). 
At initial evaluation, 183 patients (91%) were asymptom- 
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Figure 2. Occurrence of hypertrophic cardiomyopathy-related deaths 
and cardiovascular (C-V) events during the follow-up eriod in the 202 
study patients (Kaplan-Meier stimates). Top curve, General cumula- 
tive cardiovascular su vival. The study design required patients ohave 
->1 year of follow-up. Bottom curve, Cumulative event-free rate. For 
each patient, he cardiovascular event that occurred first served as the 
end point, irrespective of whether the patient subsequently died. The 
area between the two curves reflects the proportion ofpatients who 
have survived one or more cardiovascular events. The major cardio- 
vascular events are detailed inthe text. 
atic or had mild symptoms (functional class I or II); 19 other 
patients (9%) had moderate to severe symptoms (class III or 
IV). One asymptomatic patient entered the study group by 
virtue of an episode of ventricular fibrillation from which she 
was successfully resuscitated. At most recent evaluation, 154 
patients (76%) were either asymptomatic or had mild symp- 
toms, including 2 who died suddenly and unexpectedly; 48 
other patients (24%) had moderate to severe symptoms, and 
11 of these ultimately had heart failure-related death. There- 
fore, overall longitudinal analysis of the 202 study patients 
showed that the vast majority (n = 154) had a benign and 
stable clinical course, including 51 who remained completely 
symptom-free during follow-up. 
Subgroup analysis howed that he condition of 50 (25%) of 
the 202 patients deteriorated by one or more functional 
classes; of these 50 patients, 34 who initially had no or mild 
symptoms eventually had moderate or severe symptoms with 
an annual deterioration rate of 1.7%. Conversely, only 16 
patients (8%) had improvement by one or more functional 
classes with treatment, including 5 patients with moderate to 
severe symptoms who later had no or mild symptoms (Fig. 1). 
Cardiovascular events. Clinical course was also character- 
ized with respect to the occurrence (in 75 patients, 37%) of one 
or more of the following acute potentially unfavorable cardio- 
vascular events: atrial fibrillation, peripheral embolization, 
abrupt worsening of congestive symptoms (often with acute 
pulmonary edema), bradyarrhythmias or conduction abnor- 
malities requiring a permanent pacemaker, bacterial endocar- 
ditis or syncope. For the overall study group, the annual 
cardiovascular event rate was 6% over the follow-up period; 
event-free rates at 1, 5, 10 and 15 years were 94%, 85%, 69% 
and 45%, respectively (Fig. 2). 
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Figure 3. Cumulative survival of the 57 study patients who had 
demonstrated atrial fibrillation (AF) at (or before) initial diagnosis of
hypertrophic cardiomyopathy or demonstrated his arrhythmia during 
the follow-up eriod versus that of the 145 patients without evidence of
atrial fibrillation. Cardiovascular mortality was significantly greater in 
patients with atrial fibrillation, particularly after 10 years of observa- 
tion (p < 0.005). 
At least one episode of syncope occurred in 33 patients 
(16%)--before age 25 years in 3 patients and after age 25 in 
30. In 10 of the 33 patients, the cause of syncope appeared to 
be either atrioventricular block (n = 3), sustained ventricular 
tachycardia (n = 2), atrial fibrillation (n = 2), clinically 
documented myocardial ischemia with angina and ST-T 
changes on ECG (n -- 2) or exercise-induced hypotension ( = 
1) (46). In 19 of the 33 patients, the most recent syncopal spell 
had occurred >2 years before the last evaluation; only 1 
patient died suddenly, although is death occurred 15 years 
after operation and 7 years after the last syncopal episode. 
Atrial fibrillation. Of the 202 study patients, 57 (28%) had 
atrial fibrillation (chronic in 38 and with one to five paroxysmal 
episodes in 19). Atrial fibrillation was present at or before 
initial evaluation i 21 patients (mean age 48 _ 15 years, range 
20 to 74). The other 36 patients with atrial fibrillation had sinus 
rhythm at initial evaluation but had atrial fibrillation during the 
follow-up period (mean age 53 -+ 13 years, range 24 to 75). 
Patients with atrial fibrillation showed impaired survival com- 
pared with that of other patients (p < 0.005); death most 
frequently occurred after 10 years of observation and in 
association with progressive heart failure (Fig. 3). 
At initial evaluation, 47 of the 57 patients with atrial 
fibrillation were asymptomatic or had mild symptoms, and only 
10 had moderate to severe symptoms. At most recent evalua- 
tion, only 28 patients were asymptomatic or had mild symp- 
toms; 20 had marked symptoms and 9 had died suddenly or 
prematurely of heart failure. The cumulative survival rate after 
15 years was only 76% for patients with atrial fibrillation but 
97% for patients with sinus rhythm. 
For 181 patients without evidence of atrial fibrillation at 
initial evaluation, the probability of remaining free of this 
arrhythmia during the period of observation was 90%, 77% 
and 69% after 5, 10 and 15 years, respectively (Fig. 4). Cox 
JACC Vol. 26, No. 6 CECCHI ET AL. 1533 
November 15, 1995:1529-36 HYPERTROPHIC CARDIOMYOPATHY IN TUSCANY 
Figure 4. Percent cumulative probability (Kaplan-Meier sti- 
mates) of remaining free of atrial fibrillation during the 
follow-up eriod for those 181 patients without evidence of 
atrial fibrillation at initial evaluation (A). These data are 
shown specifically with respect to left atrial (LA) size (-<40 or 
>40 mm) at initial diagnosis inB and with respect to patient 
age (-<45 or >45 years) at initial diagnosis inC. 
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regression and Kaplan-Meier estimates identified two inde- 
pendent predictors of atrial fibrillation: increased left atrial 
size (>-40 mm, p < 0.01) and older age (>45 years) at 
diagnosis (p < 0.002) (Fig. 4). 
Ambulatory Holter monitoring. At least one ambulatory 
ECG recording was obtained in 190 patients. During the initial 
48-h recording, 1 to 27 runs of nonsustained ventrieular 
tachycardia (all <10 beats) were identified in 48 patients 
(25%) hut were absent in the 2 patients with sudden cardiac 
death; an additional 29 patients howed this arrhythmia on a 
subsequent ambulatory ECG, including 2 asymptomatic sur- 
viving patients with long self-terminated runs of 25 and 36 s. Of 
these 77 patients with ventricular tachycardia, 39 proved to 
have multiple and repetitive runs on Holter recordings. Syn- 
cope occurred with similar frequency in patients with and 
without nonsustained ventricular tachycardia (14 [18%] of 77 
vs. 17 [15%] of 113, p = NS). 
Treatment. Of the 154 patients who had a stable or benign 
course, 102 had been treated with cardioactive medications in 
standard osages and in a virtually continuous fashion. Each of 
the 48 patients with severe disease or progressive worsening of 
symptoms had a trial of medical treatment; five of these 
patients ultimately had myotomy-myectomy (four had lessen- 
ing of symptoms) and one other patient underwent valvulo- 
plasty for severe mitral regurgitation but had persistent symp- 
toms. 
Amiodarone was administered in 63 patients to manage 
sustained or multiple and repetitive runs of nonsustained 
ventricular tachycardia (n = 39), to obtain cardioversion or 
control or prevent atrial fibrillation (n = 23) or to prevent 
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recurrence ofcardiac arrest (n = 1). None of these 63 patients 
died suddenly, although progressive heart failure leading to 
death developed in 6. 
Left ventricular morphology. Maximal eft ventricular wall 
thickness assessed with echocardiography was 13 to 42 mm 
(mean 23 _+ 5). The predominant area of hypertrophy was 
most commonly present in the ventricular septum (n = 178 
[88%]) but also occurred in the anterolateral free wall (n = 20 
[10%]), posterior f ee wall (n = 2 [1%]) and apex (n = 2 [1%]). 
Patterns and distribution of wall thickening were diverse: 
diffuse, involving substantial portions of ventricular septum 
and free wall (n = 115 [57%D, anterior and posterior septum 
(n = 30 [15%]); anterior septum alone (n = 31 [15%]) and 
segments other than the anterior basal septum (n = 26 [13%]) 
(4). 
Left ventricular outflow obstruction. On the basis of car- 
diac catheterization r Doppler assessment (40), 40 patients 
(20%) had basal outflow obstruction (mean >30 mm Hg, 
range to 110); the remaining 162 patients (80%) had no or a 
small gradient (<30 mm Hg). Of the 57 patients with cardiac 
catheterization, 6 showed labile obstruction with basal gradi- 
ents <30 mm Hg that increased with provocative maneuvers to
---50 mm Hg (range to 116) (2,47). Cox regression analysis 
showed no relation between the presence of basal outflow 
obstruction and cardiovascular death (p = 0.19). 
In 38 of the 40 patients with basal outflow tract obstruction, 
the mechanism by which obstruction occurred under basal 
conditions was dynamic (due to mitral valve-septal contact). 
The other two patients howed midcavity muscular obstruction 
resulting from systolic apposition of septum and papillary 
muscle (13), associated in one patient with anomalous papil- 
lary muscle insertion directly into anterior mitral eaflet (48). 
Family history. Pedigrees of the study patients were not 
assessed systematically with echocardiography (40). However, 
in 86 (43%) of the 202 patients, genetic transmission of 
hypertrophic cardiomyopathy was evident by virtue of clinical 
or echocardiographic do umentation, r both, of the disease in 
a relative or by a family history of premature sudden cardiac 
death (age <50 years) judged to he probably due to hypertro- 
phic cardiomyopathy. 
Discuss ion  
Impact of patient selection on risk evaluation in hypertro- 
phic cardiomyopathy. Since the initial clinical descriptions of
hypertrophic cardiomyopathy in the early 1960s, most infor- 
mation comprising our knowledge of this disease has emanated 
from a few large referral centers (18-32). However, patients 
with hypertrophic ardiomyopathy demonstrate substantial 
diversity with respect o clinical presentation and prognosis 
(1-35,49); usually the most severely affected patients or those 
regarded at increased risk have been selectively referred to 
such tertiary centers for evaluation and treatment (33,35, 
36,49). Therefore, many published reports of patients with 
hypertrophic cardiomyopathy have probably been unavoidably 
exposed to a substantial degree of bias in patient selection, and 
as a consequence the perception of risk in this disease may 
have been exaggerated (33,36,49). 
For these reasons, it is important to access data related to 
the natural history and prognosis of patients with hypertrophic 
cardiomyopathy from populations dissimilar to those of the 
aforementioned referral-based institutions (36,49). It is our 
expectation that this process will ultimately define in more 
realistic and accurate terms the overall patient population and 
disease process in hypertrophic cardiomyopathy. 
Study findings. The present study group of >200 patients 
with hypertrophic cardiomyopathy was evaluated over a con- 
siderable period of time from a well defined geographic region 
in central Italy. This population isvirtually confined to patients 
with hypertrophic cardiomyopathy who have lived their entire 
lives in the Tuscany region and consequently is free of the 
referral patterns that predominate in North America nd many 
parts of Europe. Indeed, our study patients comprise abroad 
range in age from young children to the elderly, but they also 
closely resemble previously described patient populations with 
hypertrophic cardiomyopathy (1,2,4,5,7,15,36,47) with respect 
to disease xpression (e.g., pattems of left ventricular hyper- 
trophy and prevalence ofventricular arrhythmia and subaortic 
obstruction). 
In contrast, in regard to clinical course, the present popu- 
lation with hypertrophic cardiomyopathy differed considerably 
from the experience of referral centers (18-32). Whereas 
severe symptoms were initially present in only -10% of our 
patients, most other reports (18-21,23,24,33,37) describe 
marked symptoms in -50% of patients. Furthermore, our 
experience was not consistent with the characterization f 
hypertrophic cardiomyopathy as generally a progressive disor- 
der. More than 70% of the study patients howed relative 
stability or even improvement in functional state. An impor- 
tant minority, despite treatment, experienced deterioration or
death, which was most commonly due to progressive heart 
failure. The present study patients were generally given med- 
ical therapy in a systematic and consistent fashion, with a high 
level of continuity of care over an extended time period; 
indications for electrophysiologic testing or surgery were con- 
servative, but amiodarone was administered for multiple and 
repetitive nonsustained ventricular tachycardia (50). Indeed, 
we believe that our medical treatment s rategies were success- 
ful in controlling symptoms in many patients, although not 
particularly effective in reversing more severe symptoms once 
these became stablished. 
Sudden death. We found the rate of occurrence ofsudden 
cardiac death, to be substantially lower than that previously 
reported in most large series of patients with hypertrophic 
cardiomyopathy (18-25,27,29,32). The vast majority of pub- 
lished reports describe mortality rates, due primarily to sudden 
death (unassociated with severe heart failure) in the range of 
2% to 4% (1,2,18-21,23,24,26,31-33) andup to 6% in child- 
hood (27,29,32). In contrast, in the present study, only two 
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patients died suddenly and unexpectedly over the 1- to 30-year 
follow-up period, with an annual mortality rate of only 0.1%. 
There are several possible explanations for the relative 
infrequency of sudden cardiac death in our patients. First, the 
risks inherent in the hypertrophic cardiomyopathy disease 
process described here may be reduced simply because this 
particular patient population was subjected to very limited 
referral selection bias (49). Although possible, at present here 
is no evidence that a unique genetic substrate exists in the 
Tuscany region contributing to the relatively benign expression 
of hypertrophic cardiomyopathy observed. Second, administra- 
tion of amiodarone to a substantial patient subgroup judged to 
be at increased risk due to repetitive nonsustained ventricular 
tachycardia (or atrial fibrillation) may well have contributed 
importantly to our low frequency of sudden death (50). Finally, 
we separated the occurrence of pure sudden cardiac death 
from sudden collapse occurring in the context of severe 
congestive heart failure, and this methodology may have 
contributed to the different reported prevalence of sudden 
death in the present study compared with that in some 
previous reports (24). Although some investigators (19,51) 
have suggested that syncope harbors ominous prognostic sig- 
nificance in hypertrophic cardiomyopathy, the present data do 
not support an unfavorable prognosis for adult patients with 
hypertrophic cardiomyopathy and syncope. None of the 30 
such patients we evaluated had repeated syncopal events or 
subsequently died suddenly. 
Atrial fibrillation. Our observation of a relatively high 
prevalence of premature death due to progressive heart failure 
(in contrast to true sudden cardiac death) differs from that of 
many previous reports (18-21,23,24,26-29,31,32). Also, we 
found that atrial fibrillation was a major risk factor for poor 
prognosis and was the clinical event with the most important 
impact on disease progression. Atrial fibrillation developed 
in >25% of our study group and >50% of patients with this 
arrhythmia experienced isease progression or died during 
the study period; indeed, atrial fibrillation occurred in 70% 
of those study patients who died. Independent risk predic- 
tors most strongly associated with the development of atrial 
fibrillation proved to be left atrial enlargement and older 
age at diagnosis. These findings support the view that atrial 
fibrillation in hypertrophic cardiomyopathy is a marker of 
more advanced disease that may importantly impair clinical 
course as a result of peripheral embolization or the loss of 
the atrial systolic contribution to ventricular filling critical to 
these patients with poorly compliant ventricles (52). In this 
regard, our observations contrast with those of Robinson et 
al. (53), who reported similar clinical consequences in 
patients with hypertrophic cardiomyopathy with or without 
atrial fibrillation. 
We acknowledge the technical assistance of Mascia Adelaar, PhD, Mauricette 
Samoun, MD, and Elena Alphandery. 
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